Skip to main content

Table 3 Factors influencing KRAS testing in metastatic CRC patients

From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer

 

KRAS testing

n = 190/290 (65.5%)

Univariate analysis

P-Value

Multivariate analysis

Odds ratio

95% CI

P-Value

Age (years)

 

< 0.0001

  

< 0.0001

  > 75

42 / 107 (39.3%)

 

1

Ref

 

 60–75

97 / 126 (77.0%)

 

4.72

2.54–8.77

 

  < 60

51 / 57 (89.5%)

 

10.78

4.07–28.50

 

Sex

 

0.016

  

0.33

 Women

82 / 140 (58.6%)

 

1

Ref

 

 Men

108 / 150 (72.0%)

 

1.34

0.75–2.41

 

Site of the primary tumour

 

0.0011

  

0.006

 Rectum

35 / 64 (54.7%)

 

1

Ref

 

 Right colon

51 / 90 (56.7%)

 

1.44

0.67–3.07

 

 Left colon

104 / 136 (76.5%)

 

3.09

1.48–6.45

 

Tumour grade (MD = 40)

 

0.52

   

 Well

63 / 89 (70.8%)

    

 Moderate

83 / 131 (63.4%)

    

 Poor

20 / 30 (66.7%)

    

Geographical area of primary treatment (MD = 2)

 

0.0001

  

0.010

 Charente-Maritime

42 / 87 (48.3%)

 

1

Ref

 

 Charente

32 / 53 (60.4%)

 

1.99

0.89–4.46

 

 Deux-Sèvres

37 / 45 (82.2%)

 

4.64

1.77–12.18

 

 Vienne

61 / 79 (77.2%)

 

2.88

1.36–6.13

 

 Outside the region

17 / 24 (70.8%)

 

2.02

0.67–6.12

 

Status of the center (MD = 2)

 

0.026a

   

 Public Hospital

60 / 83 (72.3%)

 

 Private hospital

83 / 143 (58.0%)

    

 University hospital

46 / 62 (74.2%)

    
  1. 95% CI 95% confidence interval, MD missing data, Ref reference
  2. aNot retained in the final multivariate model